Privacy settings

We use technical cookies, that are necessary for the management of the website, statistical cookies and marketing cookies (including third parties cookies) for displaying individual offers and ads. For more information read our Privacy Policy. Statistical cookies and marketing cookies (inclusive of third parties cookies) are used only with your consent. By clicking “Select all and agree” you consent to our use of statistical and/or marketing cookies (inclusive of third parties cookies).

To customize your privacy settings, tick your preferences in the checkboxes and click “Apply selection”. You can always change the privacy settings and deactivate cookies by following the instructions in the Privacy Policy.

Show preferences Select all and accept
IMA is loading

3rd International Symposium on Continuous Manufacturing of Pharmaceuticals • London (UK), 03-04 October 2018

Post published on 25/09/2018

IMA Active at the 3rd International Symposium on Continuous Manufacturing of Pharmaceuticals

IMA Active is pleased to take part in the 3rd International Symposium on Continuous Manufacturing of Pharmaceuticals, which will be held at the Grange St. Paul’s Hotel, in London (UK), on October 03-04, 2018.

The symposium will bring together pharmaceutical company end users, suppliers, regulators and academics to look at accelerating adoption of Continuous Manufacturing for both small molecules and biologic products and how research groups, globally, might collaborate more to help drive this. An enormous opportunity to guide the way in which new technologies and new approaches in the pharmaceutical industry can transform quality, cost and service for the benefit of the patient.

Nicola Gandolfi, IMA Active Technical Manager for Granulation and Coating, will held the presentation “Prexima and Croma, integrated technologies for Continuous Manufacturing”.

Objectives

  • Continue and accelerate implementation based on progress made since 2014 Symposium
  • Provide practical guidance based on real case studies
  • Identify remaining gaps and develop appropriate solutions and next steps
  • Continue to engage key stakeholders (academic, industry and regulators)
  • 2014 White papers and 2016 symposium output can lay the foundation of a future ICH guideline

Themes

  • Small Molecules
  • Bioprocessing
  • Vendor Perspective
  • Supply Chain Implications
  • Regulatory

Get in touch

For any further information

Other Updates

keyboard_arrow_left keyboard_arrow_right